Reference pricing changes to cost industry €650 million in Spain
This article was originally published in Scrip
Executive Summary
Not long after taking power, Spain's new government has signed into law changes to the reference pricing system, which will cost the pharmaceutical industry some €650 million. The new changes will exacerbate already tough market conditions and add to government measures introduced in 2011 aimed at shaving €2.4 billion off the drugs bill, says Farmaindustria, the association representing the R&D-based pharmaceutical industry.